论文部分内容阅读
肿瘤坏死因子相关凋亡诱导配体(tumor necrosis factor-related apoptosis-inducing ligand,TRAIL)具选择性诱导肿瘤细胞凋亡作用。研究发现其死亡受体在多数胶质瘤中表达。近年研究认为TRAIL诱导胶质瘤细胞凋亡作用途径主要有胞外线粒体非依赖性途径和胞内线粒体途径。研究还发现将TRAIL与传统及新兴的多种治疗方式联合治疗胶质瘤可发挥协同作用,基因治疗的发展和给药方式的改进促进了TRAIL及其受体在胶质瘤治疗的作用发挥,使得TRAIL成为胶质瘤联合治疗的一种理想的选择。本文在TRAIL及其受体在胶质瘤的表达,作用机制,治疗方式进展等方面进行探讨并进行展望。
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces tumor cell apoptosis. The study found that its death receptor is expressed in most gliomas. Recent studies suggest that TRAIL induced glioma cell apoptosis pathway mainly extracellular mitochondria-independent pathways and intracellular mitochondrial pathway. The study also found that the combination of TRAIL and traditional and emerging treatment of glioma synergy can play a synergistic role in the development of gene therapy and administration improved the promotion of TRAIL and its receptors in the role of glioma treatment, Making TRAIL an ideal choice for combination therapy of glioma. In this paper, the expression of TRAIL and its receptor in glioma, the mechanism of action, the progress of treatment and so on to explore and prospects.